Pembrolizumab with chemoradiotherapy [PEMB36]

Pembrolizumab with chemoradiotherapy for untreated locally advanced cervical cancer where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with pembrolizumab in combination with chemoradiotherapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has a histologically or cytologically determined diagnosis of locally advanced cervical cancer and has had no prior treatment.
3. The patient has disease which is staged as below according to FIGO 2014 • Stage 3A-C • Stage 4A
4. Pembrolizumab will be given in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) and then continued as monotherapy up to a maximun duration of 2 years treatment.
5. Treatment with pembrolizumab will be administered as either every 3 weeks or every 6 weeks until disease progression, unacceptable toxicity, withdrawal of patient consent or up to 24 months whichever occurs first. The licensed dose and frequency of pembrolizumab will be used as shown below • 395mg every 3 weeks, or 790mg every 6 weeks if given via subcutaneous injection • 200mg every 3 weeks, or 400mg every 6 weeks if given via intravenous infusion
6. The patient has a current ECOG performance status of 0 or 1.
7. When a treatment break of more than 12 weeks beyond the expected 3-, or 6-weekly cycle length is needed, the prescribing clinician will complete a treatment break approval form to restart treatment. This must be approved before pembrolizumab is re-commenced.
8. Pembrolizumab will be otherwise used as set out in its Summary of Product Characteristics (SPC).

CDF funded From: 25 June 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Note

The data on this page was produced using version 1.405 of the CDF list, downloaded from NHS England’s website on 02 July 2026 at 11:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.